Ivan Ackerman, MD
Pulmonary Disease · Brandon, FLNPI 1609836089
Payments from drug & device makers
Across 363 payments — averaging $157.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$25K
- Mylan Specialty L.p.$16K
- Harmony Biosciences LLC$7K
- Insmed, Inc.$5K
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$428
- plus $3K from 28 others
What the payments were for
- Consulting fees$11,58121%
- Speaking & faculty fees$37,22367%
- Travel & lodging$280%
- Food & beverage$6,47312%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 96 | $24,980 |
| Mylan Specialty L.p. | 35 | $16,251 |
| Harmony Biosciences LLC | 18 | $7,391 |
| Insmed, Inc. | 19 | $4,615 |
| AstraZeneca | 62 | $1,007 |
| Jazz Pharmaceuticals Inc. | 19 | $428 |
| Boehringer Ingelheim | 20 | $359 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $309 |
| Regeneron Healthcare Solutions, Inc. | 8 | $306 |
| Electromed, Inc. | 13 | $263 |
| Inspire Medical Systems, Inc. | 2 | $218 |
| Mallinckrodt Hospital Products Inc. | 7 | $170 |
| Philips North America LLC | 8 | $149 |
| Sanofi | 6 | $147 |
| Amgen | 5 | $112 |
| Grifols USA, LLC | 3 | $72 |
| Inogen, Inc. | 4 | $49 |
| Sunovion Pharmaceuticals Inc. | 5 | $49 |
| Verona Pharma, Inc. | 2 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $42 |
| Baxter Healthcare | 2 | $39 |
| Pulmonx Corporation | 1 | $37 |
| Phadia US Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $33 |
| United Therapeutics Corporation | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Vapotherm Inc | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Pharming Healthcare, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $20 |
| Circassia Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,346 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 985 | $824,860 |
| XywavSodium,calcium,mag,pot Oxybate | 25 | $486,920 |
| OfevNintedanib Esylate | 25 | $323,533 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $235,345 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 247 | $196,237 |
| WakixPitolisant Hcl | 12 | $176,092 |
| Spiriva RespimatTiotropium Bromide | 205 | $153,191 |
| SymbicortBudesonide/Formoterol Fumarate | 251 | $79,846 |
| Spiriva HandihalerTiotropium Bromide | 83 | $69,899 |
| Advair HfaFluticasone Propion/Salmeterol | 159 | $67,260 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,653 | $50,169 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $49,595 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $39,318 |
| EliquisApixaban | 49 | $39,004 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 254 | $35,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $24,980 | $939,3661,197 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $359 | $530,676298 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $1,007 | $302,293551 claims |
| Grifols USA, LLCProlastin C | $72 | $235,34523 claims |
| Harmony Biosciences LLCWakix | $7,391 | $176,09212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Brandon
- Daniel LorchBrandon$5.5M
- Dragos ZanchiBrandon$1M
- Richard PowellBrandon$1M
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Lourdes BoschMiami$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.